Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ofloxacin + ornidazole
- Development stage
- Unknown
- Lead developer
- Mits Healthcare
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Parenteral
01
Overview
ofloxacin + ornidazole is a fixed-dose combination antibiotic and antiprotozoal medication. Ofloxacin is a second-generation fluoroquinolone that exerts its antibacterial effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. Ornidazole is a nitroimidazole derivative that, upon reduction within the target cell, forms reactive intermediates that interact with DNA, leading to the loss of helical structure and strand breakage, which inhibits protein synthesis and causes cell death in susceptible anaerobic bacteria and protozoa. This combination is primarily indicated for the treatment of mixed infections caused by aerobic and anaerobic bacteria or protozoa, including acute diarrhea, dysentery, gynecological infections, and respiratory tract infections.
- Brand names
- OFLOMITS-OZO2O-2O 2Zenflox OZOrnofOflomac OZ
- Other names
- ofloxacin and ornidazole
02
Targets
Topo IV (Bacterial Topoisomerase IV)DNA gyrase
Beyond the preview
Go deeper on ofloxacin + ornidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ofloxacin + ornidazole.